Consider the Role of Ongentys and Kynmobi for Parkinson’s Disease

December 2020

Ongentys (opicapone) and Kynmobi (apomorphine) will add to the growing list of new meds for Parkinson’s disease.

They’re for “off” episodes...when symptoms (tremor, etc) return between carbidopa/levodopa doses, especially as Parkinson’s progresses.

Optimize carbidopa/levodopa first...such as with more frequent dosing. Put the role of the new meds in perspective.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote